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Bipolar I disorder is a chronic disorder characterized by episodic recurrences of mania,
depression, and mixed affective states interspersed with periods of full or partial remission;
subsyndromal residual symptoms between episodes are common and disabling. Cariprazine, an
atypical antipsychotic, is a potent dopamine D3 and D2 receptor partial agonist with
preferential binding to D3 receptors. Post-hoc analyses of pooled data from 3 positive trials
were conducted to evaluate the effect of cariprazine 3–12 mg/d on the symptoms of mania in
inpatients (18–65 years) with bipolar I disorder and a current manic episode. Analyses were
based on the pooled intent-to-treat (ITT) population (placebo=429; cariprazine=608). Mean
change from baseline to the end of treatment on individual Young Mania Rating Scale (YMRS)
items was analysed using a mixed-effects model for repeated measures (MMRM); categorical
symptom severity shifts were analysed using logistic regression. Statistically signiﬁcant
improvement in mean change was seen for cariprazine versus placebo on all 11 YMRS items
(po0.0001); signiﬁcantly more cariprazine- versus placebo-treated patients had mild/no
symptoms at the end of treatment on 11 YMRS items (po0.0001) and concurrently on the
4 YMRS core symptoms (irritability, speech, content, and disruptive–aggressive behaviour)
(po0.0001). Signiﬁcantly more cariprazine- versus placebo-treated patients shifted from a
Moderate/Worse or Marked/Worse Symptoms categories to Mild/No Symptoms on all 11
(po0.0001) and 9 of 11 YMRS items (po0.05), respectively. Results suggest that cariprazineo.2015.08.020
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1883Effect of cariprazine across the symptoms of mania in bipolar I disordertreatment improved mania across YMRS symptoms; a signiﬁcant percentage of cariprazine-
versus placebo-treated patients had mild/no symptoms at the end of treatment.
& 2015 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Bipolar I disorder is a chronic and disabling disorder
characterized by episodic recurrences of mania, hypomania,
depression, and mixed affective states interspersed with
periods of full or partial remission. The hallmark diagnostic
feature of bipolar disorder is a manic episode, which is
classically described as a state of euphoria, although
intense irritability, agitation, and psychotic features are
common (American Psychiatric Association, 2013). Mania is
characterized by a broad array of symptoms including
grandiosity, mood lability, decreased need for sleep, and
cognitive impairment (Leboyer and Kupfer, 2010); patients
may also experience psychotic symptoms, impaired func-
tioning, substance abuse, and anxiety disorders (Judd et al.,
2005; Sachs et al., 2011). During a manic episode, indivi-
duals may not perceive that they need treatment, although
consequences of poor judgment, hyperactivity, and lack of
insight are severe enough to profoundly impair social and
professional functioning or to require hospitalisation.
Between full syndromal affective episodes, the majority
of patients with bipolar disorder spend almost 50% of their
time unwell due to subsyndromal symptoms that persist
after the treatment and resolution of an acute episode
(Altshuler et al., 2002; Joffe et al., 2004; Judd et al., 2002;
Vieta et al., 2008). Subsyndromal residual symptoms are
associated with diminished quality of life, functional impair-
ment, and risk of early relapse and recurrence (Judd et al.,
2008; Tohen et al., 2006). Although several pharmacothera-
pies from various drug classes are approved for the treat-
ment of bipolar mania (Jann, 2014), all agents are not
effective in all patients and the high incidence of residual
symptoms and recurrence demonstrate the need for addi-
tional treatments with strong efﬁcacy across the range of
acute symptoms. Comprehensive symptomatic improvement
and recovery may improve the occurrence of residual
symptoms, helping to decrease relapse and improve overall
patient well-being in bipolar disorder.
While controlled clinical trials provide important data
about the ability of an agent to reduce manic symptoms,
mean change from baseline on a validated rating scale may
not be the only outcome measure that is relevant to a
clinician treating bipolar disorder. Using procedures
adopted from meta-analyses, (Riley et al., 2010) innovative
analyses can be conducted on data recorded from individual
patients in clinical trials, so called patient-level data. By
pooling these data from similarly designed trials to create a
single dataset, statistical power is increased compared to
the individual studies themselves allowing for patient sub-
group analyses, examination of treatment effects across
individuals, and adjustment for baseline factors. Unlike
aggregate data, which provides averaged or estimated
results from across all individuals in a study, patient-leveldata goes beyond mean change to identify clinically mean-
ingful improvement in individual patients. Recent trends in
psychiatric research advocate for ﬁner grain analysis of
clinical dimensions and symptoms, so called “molecular
psychopathology” (Vieta, 2014), moving away from the
broad syndromes and approaching “precision psychiatry”
(Vieta, 2015).
Based on positive clinical trial evidence and favourable
short-term adverse effect proﬁles, monotherapy with an
atypical antipsychotic agent is a recommended ﬁrst-line
treatment for mania associated with bipolar disorder (Nivoli
et al., 2011). Cariprazine, an atypical antipsychotic candi-
date, is a potent dopamine D3 and D2 receptor partial
agonist with preferential in vitro binding to D3 receptors.
It is currently being investigated for the treatment of
schizophrenia, bipolar mania, bipolar depression, and as
an adjunctive treatment for major depressive disorder
(MDD). Cariprazine has demonstrated efﬁcacy and toler-
ability in 3 phase II or phase III clinical trials of adult
patients with bipolar I disorder. The primary efﬁcacy para-
meter in each of these 3 positive studies was change from
baseline to week 3 in Young Mania Rating Scale (YMRS)
(Young et al., 1978) total score. The YMRS is an 11-item
clinician-rated scale that measures the severity of mania
symptoms.
Post-hoc analyses of pooled patient-level data from the
3 positive clinical trials were conducted to evaluate the
effect of cariprazine on the symptoms of bipolar mania.
Analyses included assessments of change on the individual
items of the YMRS and the YMRS core items (irritability,
speech, content, disruptive/aggressive behaviour), and
novel category shift analyses that evaluated the percentage
of patients who improved from a more severe level of
baseline symptoms to mild or no symptoms at the end of
treatment.2. Experimental procedures
2.1. Study design
Data were pooled from the 3 similarly designed, randomized,
placebo-controlled, double-blind, multicenter, parallel-group
studies of cariprazine in adult patients with bipolar I disorder;
detailed methods of the constituent studies are published
elsewhere (Calabrese et al., 2015; Durgam et al., 2015; Sachs
et al., 2015). In brief, each study had a washout period of up to
1 week followed by 3 weeks of double-blind treatment and a
2-week safety follow-up period; patients were hospitalised
during screening and for a minimum of 2 weeks of treatment.
Two of the trials (RGH‑MD‑31 [NCT00488618] and RGH‑MD‑32
[NCT01058096]) used ﬂexibly dosed cariprazine 3–12 mg/d; one
trial (RGH‑MD‑33 [NCT01058668]) had a ﬁxed/ﬂexible-dose
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12 mg/d).
2.2. Patients
Male and female inpatients (18–65 years of age, inclusive)
with a diagnosis of bipolar I disorder based on Diagnostic
and Statistical Manual of Mental Disorders, 4th ed, text
revision (DSM-IV-TR) (American Psychiatric Association,
2000) and an acute manic or mixed episode were included
in the constituent studies; patients currently experiencing a
ﬁrst manic episode were excluded. Patients were required
to have a YMRS total score Z20, a score Z4 on at least 2 of
the 4 core YMRS items, and a Montgomery–Åsberg Depres-
sion Rating Scale (MADRS) (Montgomery and Asberg, 1979)
total score o18.
Key exclusion criteria were typical of studies conducted
in bipolar I disorder and included patients who met the
criteria for a principal DSM-IV-TR–based axis I diagnosis
other than bipolar I (conduct disorder, obsessive–compulsive
disorder, and anxiety disorders were allowed), rapid cycling,
substance abuse, or suicide risk deﬁned as a past year
attempt, score Z5 on MADRS item 10 (Suicidal Thoughts),
or results of psychiatric interview or the Columbia-Suicide
Severity Rating Scale (C-SSRS) (Posner et al., 2011).
2.3. Post-hoc analyses
Post-hoc analyses were based on the YMRS, a scale that has
4 well-described anchor points for each of its 11 items to
grade the severity of the symptom, with higher scores
indicating greater severity. On 7 of the items (elevated
mood, increased motor activity, sexual interest, sleep,
language–thought disorder, appearance, and insight),
anchor point scores range from 0 (absence of the symptom
or normal, appropriate behaviour) to 4 (most severe). On
the 4 core items of the YMRS (irritability, speech [rate and
amount], content, and disruptive–aggressive behaviour),
anchor points are given twice the weight to compensate
for poor cooperation from severely ill patients and the
scores range from 0 (absence of the symptom) to 8 (most
severe).
Post-hoc outcomes of interest were mean change from
baseline to the end of the study on the individual items of
the YMRS; the percentage of patients at the end of the
study that had mild or no symptoms on all 11 YMRS
individual items (score o2 on 0–4 items or o4 on the core
items); the percentage of patients at the end of the study
that had mild or no symptoms on all 4 core items of the
YMRS concurrently (irritability, speech, content, disruptive/
aggressive behaviour item scores o4); and the percentage
of patients that improved in a novel categorical shift
analyses from a more severe symptom category at baseline
to a less severe symptom category at the end of the study.
In the categorical shift analyses, evaluations were con-
ducted on each of the 11 individual items of the YMRS
(items scored 0–4 or 0–8); a separate analysis was also
performed to evaluate shift on the 4 YMRS core items
concurrently (items scored 0–8). To quantify a shift, the
score for each anchor point description was given a severity
rating. On items with a score range of 0–4, a score of 0=nosymptoms; 1=mild symptoms; 2=moderate symptoms;
3=marked symptoms; 4=severe symptoms. On the core
items with a score range of 0–8, a score of 0=no symptoms;
2=mild symptoms; 4=moderate symptoms; 6=marked
symptoms; 8=severe symptoms. For the shift analysis,
severity ratings were then grouped into categories deﬁned
as “Mild/No Symptoms” (YMRS score o2 [0–4 items] or o4
[core items]), “Moderate/Worse Symptoms” (YMRS score
Z2 [0–4 items] or Z4 [core items]), and “Marked/Worse
Symptoms” (YMRS score Z3 [0–4 items] or Z6 [core
items]).
The percentage of patients who shifted from a more
severe category to a less severe category on each of the 11
individual YMRS items and the percentage of patients who
shifted on all 4 YMRS core items concurrently were eval-
uated using 2 severity criteria. For the ﬁrst severity
criterion, the percentage of patients that shifted from the
Moderate/Worse Symptoms category at baseline to the
Mild/No Symptoms category at week 3 was evaluated. For
the second severity criterion, the percentage of patients
that shifted from the Marked/Worse Symptoms severity
category at baseline to the Mild/No Symptoms category at
week 3 was evaluated.
2.4. Statistical analyses
Analyses were based on the pooled intent-to-treat (ITT)
population, which consisted of all patients who received
study medication and had Z1 postbaseline YMRS assess-
ment. All cariprazine doses (3–12 mg/d) were pooled for
these post-hoc analyses. Mean change from baseline to the
end of week 3 on the YMRS individual items was analysed
using a mixed-effects model for repeated measures
(MMRM), with treatment group, study, study centre within
study, visit, and treatment-group-by-visit interaction as
ﬁxed effects and baseline YMRS score and baseline-by-visit
interaction as covariates; an unstructured covariance
matrix was used to model the covariance of within-patient
scores. Effect sizes were calculated for changes from base-
line on the individual items of the YMRS using Cohen's d.
YMRS category shift analyses were based on a logistic
regression model with study, treatment group, and baseline
values as explanatory variables; missing values were
imputed using the last observation carried forward (LOCF)
approach. Odds ratio (OR) and p values were calculated for
each comparison of cariprazine versus placebo; p values for
post-hoc analyses were not adjusted for multiple compar-
isons. All statistical tests were 2-sided at the 5% signiﬁcance
level.
3. Results
3.1. Patient disposition and baseline
characteristics
A total of 1065 patients received double-blind treatment in
the 3 studies (pooled safety population); 1037 patients in
the safety population additionally had a valid postbaseline
YMRS assessment and comprised the pooled ITT population
(placebo=429; cariprazine=608). Demographic and base-
line characteristics for the pooled population are presented
Table 1 Demographic and baseline characteristics (pooled ITT population).
Characteristics Placebo Cariprazine 3–12 mg/d
n=429 n=608
Age, mean (SD), years 39.0 (11.6) 39.7 (11.7)
Men, n (%) 259 (60) 358 (59)
Race, n (%)
White 201 (47) 309 (51)
Black 102 (24) 163 (27)
Asian 116 (27) 125 (21)
Other 10 (2) 11 (2)
Weight, mean (SD), kg 77.5 (19.2) 77.5 (19.0)
Body mass index, mean (SD), kg/m2 27.0 (5.7) 27.0 (5.7)
Psychiatric history
Bipolar I duration, mean (SD), years 12.9 (9.0) 13.4 (9.8)
Duration of current episode, % of patients
r7 days 11 11
8–14 days 41 39
15–21 days 15 17
421 days 33 34
ITT indicates intent-to-treat.
Table 2 Severity of symptoms in the pooled population at baseline (pooled ITT population).
YMRS individual items Treatment groups n Baseline
score, mean (SD)
Moderate/worse baseline
severity, n (%)
Marked/worse baseline
severity, n (%)
Elevated mood Placebo 429 2.9 (0.8) 416 (97.0) 325 (75.8)
Cariprazine 608 3.0 (0.8) 581 (95.6) 474 (78.0)
Increased motor activ-
ity-energy
Placebo 429 2.9 (0.7) 414 (97.0) 347 (80.9)
Cariprazine 608 2.9 (0.7) 590 (97.0) 505 (83.1)
Sexual interest Placebo 429 1.5 (1.2) 233 (54.3) 96 (22.4)
Cariprazine 608 1.8 (1.2) 375 (61.7) 189 (31.1)
Sleep Placebo 429 2.6 (0.9) 387 (90.2) 255 (59.4)
Cariprazine 608 2.6 (0.8) 556 (91.4) 396 (65.1)
Irritabilitya Placebo 429 4.2 (1.3) 351 (81.8) 75 (17.5)
Cariprazine 608 4.3 (1.3) 503 (82.7) 114 (18.8)
Speecha Placebo 429 4.7 (1.3) 386 (90.0) 138 (32.2)
Cariprazine 608 4.7 (1.4) 549 (90.3) 199 (32.7)
Language–thought
disorder
Placebo 429 2.4 (0.6) 403 (93.9) 179 (41.7)
Cariprazine 608 2.4 (0.6) 572 (94.1) 259 (42.6)
Contenta Placebo 429 4.9 (2.0) 332 (77.4) 202 (47.1)
Cariprazine 608 4.8 (1.9) 474 (78.0) 254 (41.8)
Disruptive–aggressive
behavioura
Placebo 429 3.2 (1.5) 209 (48.7) 23 (5.4)
Cariprazine 608 3.3 (1.4) 303 (49.8) 32 (5.3)
Appearance Placebo 429 1.3 (1.0) 175 (40.8) 46 (10.7)
Cariprazine 608 1.4 (1.0) 267 (43.9) 88 (14.5)
Insight Placebo 429 1.2 (1.3) 153 (35.7) 90 (21.0)
Cariprazine 608 1.3 (1.4) 242 (39.8) 151 (24.8)
ITT indicates intent-to-treat; YMRS, Young Mania Rating Scale.
aIndicates the core items of the YMRS (score range of 0-8; 0=no symptoms; 2=mild; 4=moderate; 6=marked; 8=severe; for YMRS
items other than core items, the score range is 0–4 (0=symptoms; 1=mild; 2=moderate; 3=marked; 4=severe). Moderate/worse
severity indicates YMRS score Z2 (0–4 items) or Z4 (core items); Marked/Worse Severity indicates YMRS score Z3 (0–4 items) or Z6
(core items).
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age was 39–40 years, and the mean duration of bipolar I
disorder was 12–13 years.Mean (SD) baseline scores on the YMRS individual items
were similar between cariprazine- and placebo-treatment
groups (Table 2). When baseline scores were grouped into
Figure 2 YMRS single items: cariprazine effect sizes (pooled
ITT population, MMRM). Effects sizes (Cohen's d) for cariprazine
versus placebo on the YMRS single items ranged from 0.31
(increased motor activity) to 0.55 (irritability).
Note: YMRS indicates Young Mania Rating Scale.
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[core items]) or Marked/Worse Severity (score Z3 [0–4
items] or Z6 [core items]) categories, this patient popula-
tion was shown to be highly symptomatic (Table 2). Moder-
ate or worse baseline severity was seen in Z90% of patients
on the YMRS items of elevated mood, increased motor
activity-energy, sleep, language–thought disorder, and
speech, and in 450% of patients on the items of sexual
interest, irritability, and content; approximately 50% of
patients also had moderate or worse severity on the
disruptive–aggressive behaviour item. Marked or worse
baseline severity was present in more than half of patients
on the YMRS items of elevated mood, increased motor
activity-energy, and sleep; the percentage of patients with
marked or worse baseline severity on the core YMRS
disruptive–aggressive behaviour item was low (5%). The
ability to analyse the groups with marked or worse baseline
severity was hampered by small numbers of patients in some
of the symptom domains.Figure 3 Percentage of patients with mild or no symptoms on
the YMRS at the end of double-blind treatment. aScore o4 on4. YMRS item analyses
4.1. Individual items
Signiﬁcant improvement in mean change from baseline to
week 3 was seen on all 11 individual YMRS symptom items in
favour of cariprazine versus placebo (Figure 1). Substantial
treatment effects (Cohen's d) in favour of cariprazine versus
placebo were seen on all YMRS single items (Figure 2); the
largest effect sizes for cariprazine treatment were noted on
the irritability (0.55) and disruptive–aggressive behaviour
(0.49) items.Figure 1 YMRS individual items: mean change from baseline
to week 3 in the pooled ITT population (MMRM). The difference
in mean change was statistically signiﬁcant in favour of
cariprazine on all individual YMRS items. ***po0.001.
Note: YMRS indicates Young Mania Rating Scale.
the core items of the YMRS (irritability, speech, content, and
disruptive–aggressive behaviour); bscore o2 (0–4 items) or o4
(core items) on all individual YMRS items. CI indicates con-
ﬁdence interval; OR, odds ratio; YMRS, Young Mania Rating
Scale. ***po0.001.At the end of double-blind treatment, a signiﬁcantly
higher percentage of cariprazine-treated patients than
placebo-treated patients had mild or no symptoms (score
o2 [0–4 items] oro4 [core items]) on all 11 YMRS items (OR
versus placebo=1.9; po0.0001) (Figure 3). A signiﬁcantly
higher percentage of cariprazine-treated patients than
placebo-treated patients also had mild or no symptoms
(score o4) concurrently on the 4 YMRS core items (irrit-
ability, speech, content, disruptive–aggressive behaviour)
(OR versus placebo=2.0; po0.0001) (Figure 3).4.2. YMRS category shift analyses
The percentage of patients that shifted from the Moderate/
Worse Symptoms category at baseline to Mild/No Symptoms
at the end of double-blind treatment was signiﬁcantly
higher for cariprazine versus placebo on all 11 YMRS
individual items (Figure 4). The effects of cariprazine as
shown by the odds ratio versus placebo for shifts on these
items ranged from 1.6 (increased motor activity-energy) to
2.7 (irritability).
Figure 4 Percentage of patients in the Moderate/Worse
Symptoms category at baseline that shifted to Mild/No Symp-
toms at the end of double-blind treatment in the pooled ITT
population. Moderate/worse was deﬁned as score Z2 (0–4
items) or Z4 (core items); mild/no symptoms was deﬁned as
score o2 (0–4 items] or o4 (core items). YMRS indicates Young
Mania Rating Scale. ***po0.0001.
Figure 5 Percentage of patients in the Marked/Worse Symp-
toms category at baseline that shifted to Mild/No Symptoms at
the end of double-blind treatment in the pooled ITT popula-
tion. Marked/Worse was deﬁned as Z3 (0–4 items) or Z6 (core
items); mild/no symptoms was deﬁned aso2 (0–4 items) oro4
(core items) at the end of double-blind treatment. YMRS
indicates Young Mania Rating Scale. *po0.05; **po0.01;
***po0.001.
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Mild/No Symptoms at the end of double-blind treatment
occurred in a signiﬁcantly greater percentage of caripra-
zine- versus placebo-treated patients on 9 of 11 YMRS
items (Figure 5); the difference in the percentage of
cariprazine- and placebo-treated patients who shifted to
Mild/No Symptoms was not statistically signiﬁcant on the
appearance or disruptive–aggressive behaviour items.Because a lower percentage of patients were markedly
impaired at baseline on the appearance (13%) and disrup-
tive–aggressive behaviour (5%) items compared with other
individual items (18–82%), this may have limited the ability
to detect a between-group difference on these items. The
greatest cariprazine treatment effect as shown by the odds
ratio versus placebo was seen on the irritability item,
where more than twice as many cariprazine patients (65%)
as placebo patients (32%) shifted from Marked/Worse
Symptoms to Mild/No Symptoms.
When concurrent shift on the 4 core YMRS items was
analysed, the percentage of patients who improved from
the Moderate/Worse Symptoms category to Mild/No Symp-
toms category at week 3 was signiﬁcantly greater in the
cariprazine group (50.5%) than in the placebo group (29.1%)
(OR versus placebo, 2.4 [1.5, 3.9], p=0.0002). No analyses
could be conducted for concurrent shift on the 4 core YMRS
items using the Marked/Worse Symptoms to Mild/No Symp-
toms severity shift criterion. The percentage of patients
with marked or worse symptom severity at baseline was only
high enough to evaluate on 3 of the 4 core YMRS items (44%,
33%, 18% for content, speech, irritability, respectively); due
to the low percentage of patients with marked or worse
symptom severity on the disruptive–aggressive behaviour
item (5%), concurrent shift of all 4 items was not evaluable.5. Discussion
Post-hoc analyses conducted on pooled patient-level data
from 3 cariprazine studies in adult patients with acute
mania associated with bipolar I disorder demonstrated
improvement across the spectrum of symptoms associated
with bipolar mania in patients treated with cariprazine.
Statistically signiﬁcant improvement for cariprazine versus
placebo was seen in mean change from baseline on all 11
individual symptoms of the YMRS; signiﬁcantly more car-
iprazine-treated patients also had mild or no symptoms on
all YMRS items and on the 4 YMRS core items concurrently at
the end of double-blind treatment. In novel categorical shift
analyses, greater percentages of cariprazine-treated
patients than placebo-treated patients improved from a
more severe YMRS symptom category at baseline to the
Mild/No Symptoms category at the end of treatment.
Acute mania is often considered a medical emergency,
with cognitive, behavioural, and psychotic features contri-
buting to the patient's disability and the necessity to ensure
their safety (Grande and Vieta, 2015). However, acute
affective episodes do not account for the total morbidity
in bipolar disorder since subsyndromal residual symptoms
greatly contribute to impaired functioning, diminished
quality of life, and faster time to relapse (Altshuler et al.,
2002; Joffe et al., 2004; Judd et al., 2008; Marangell et al.,
2009; Perlis et al., 2006; Tohen et al., 2006; Vieta et al.,
2008). Residual symptoms that remain after an acute manic
episode is considered resolved are a clinically useful pre-
dictor of bipolar relapse and a robust correlate of a more
persistent course of illness (Judd et al., 2008). Treatment
with an agent that has broad efﬁcacy across symptoms may
help patients achieve symptom-free status, which could
lead to more persistent affective stability.
E. Vieta et al.1888All atypical antipsychotics, except lurasidone and iloper-
idone, have demonstrated efﬁcacy in treating acute mania
(Jann, 2014; Nivoli et al., 2011). In spite of this apparent
class effect in bipolar mania, atypical antipsychotic agents
have different mechanisms of actions, suggesting that there
is a potential for individual differences among agents for
treating mania. To date, there is uncertainty surrounding
which speciﬁc pharmacologic activities drive efﬁcacy in
mood disorders (Horacek et al., 2006; Yatham et al.,
2005) and the hypothesis that atypical antipsychotic agents
may have antimanic differences is supported by the obser-
vation that efﬁcacy differences exist when these agents are
used to treat bipolar depression (Jann, 2014).
Cariprazine is a potent dopamine D3 and D2 receptor
partial agonist that has preferential binding to D3 receptors
(Kiss et al., 2010; Slifstein et al., 2013). At antipsychotic-
like effective doses, cariprazine shows high and balanced
occupancy at D3 and D2 receptors (Gyertyan et al., 2011;
Kiss et al., 2010) in contrast to other atypical antipsychotics
that display high occupancy at D2 receptors with lower or
negligible occupancy at D3 receptors (Graff-Guerrero et al.,
2009; Gyertyan et al., 2011; Mizrahi et al., 2011). The D3
receptor is thought to play a role in the modulation of
cognition and mood (Cho et al., 2010; Laszy et al., 2005)
and blockade of this receptor may translate into beneﬁts in
treating the broad symptoms associated with bipolar dis-
order (Beaulieu et al., 2007; Joyce and Millan, 2005;
Schwartz et al., 2000). Since different atypical antipsycho-
tic receptor proﬁles may translate into differences in
efﬁcacy and tolerability proﬁles, examining the effects of
cariprazine on the individual symptoms of mania may
extract information that elucidates subtle differences for
this agent to help inform clinical decision-making according
to the symptom proﬁle of individual manic patients.
Deconstructing an acute manic episode into individual
symptom components may be a clinically useful way to
assess patient status at baseline and at the end of acute
treatment, potentially providing information that could
enable a clinician to better manage minor, subsyndromal,
or residual symptoms between episodes, and in speciﬁc
subsets of patients. In our pooled analysis population, at
least 50% of patients had moderate or worse baseline
symptoms on all 11 YMRS items; marked or worse symptoms
were also observed for more than half the patients on
several items. Of note, more than 90% of patients had at
least a moderate baseline level of elevated mood and
increased motor activity, which are classic presenting
features of mania, while over 80% also presented with high
levels of irritability.
When mean change from baseline to week 3 on the YMRS
individual items was evaluated, statistically signiﬁcant differ-
ences in favour of cariprazine over placebo were observed on
every item, indicating improvement across the spectrum of
symptoms associated with bipolar mania. Robust effect sizes
for cariprazine were noted on most YMRS individual items
(effect size range, 0.31–0.55). The strongest effect for car-
iprazine treatment was seen on the irritability item, which is
an important consideration since many patients experience
irritability as a predominant presenting feature in patients with
acute mania (American Psychiatric Association, 2013) or mania
with depressive symptoms (Vieta et al., 2014). Although few
studies using patient-level data to evaluate symptom change inbipolar mania have been reported, it is interesting to note that
the effect sizes seen for cariprazine on the individual YMRS
items in our analysis were comparable to the effect sizes seen
in a post-hoc analysis of YMRS individual items for quetiapine
(effect sizes range, 0.24–0.57) (McIntyre et al., 2007).
Since stable recovery in bipolar disorder can only be
achieved if patients reach an asymptomatic status (Judd
et al., 2008), aggressively targeting and monitoring symp-
tom improvement during treatment may offer an opportu-
nity to improve long-term patient outcomes. Given our
highly symptomatic patient population at baseline, it is
notable that the odds of cariprazine-treated patients reach-
ing mild or no symptom status at the end of treatment on all
11 YMRS items and on the 4 core items of mania concur-
rently were 2 times that of placebo-treated patients. This
ﬁnding suggests that treatment of acute manic episodes
with cariprazine may help patients achieve a relatively
asymptomatic state that may beneﬁt functioning and
decrease risk of relapse during periods of remission.
The YMRS category shift analyses provided opportunities
to evaluate patient-level data for clinically meaningful
improvement in individual symptoms over the course of
treatment. In the Moderate/Worse Symptoms category, a
signiﬁcantly greater percentage of cariprazine- versus pla-
cebo-treated patients improved to Mild/No Symptoms on all
11 YMRS individual items, suggesting that cariprazine
patients with this level of symptom severity experienced
clinically relevant improvement across the range of manic
symptoms during the course of treatment.
In the Marked/Worse Symptoms category, a signiﬁcantly
greater percentage of cariprazine-treated patients versus
placebo-treated patients shifted to Mild/No Symptoms on
9 of 11 YMRS items, suggesting that cariprazine-treated
patients with more severe baseline impairment also experi-
enced improvement in multiple symptoms. The difference
in the percentage of cariprazine- and placebo-treated
patients who switched to the Mild/No Symptoms category
was not statistically signiﬁcant on the YMRS items of
appearance and disruptive–aggressive behaviour, which
may have been because the low percentage of patients
with baseline marked impairment on these items affected
the ability to detect a between-group difference. The small
percentage of patients with high baseline scores on the core
item of disruptive–aggressive behaviour may have addition-
ally reﬂected an inability to cooperate with study proce-
dures (e.g., failure to sign the informed consent form,
which would have prevented further study participation) for
patients with greater illness severity. Alternatively, if rescue
medication, such as a benzodiazepine, was required for
patients with more severe disruptive or aggressive beha-
viour, between-group efﬁcacy differences could have been
blunted since rescue medication was delivered to patients
whether they were on drug or placebo.
Similar to the large effect size seen in mean change from
baseline on the YMRS irritability item, the odds of shifting
from the Moderate/Worse or Marked/Worse Symptoms cate-
gories to the Mild/No Symptoms category was greatest for
cariprazine versus placebo on the irritability item, an essen-
tial diagnostic feature for mania. In patients with moderate or
worse irritability at baseline, the odds ratio for cariprazine-
treated patients were 2.7 times higher than placebo-treated
patients to shift to the Mild/No Symptoms category at the end
1889Effect of cariprazine across the symptoms of mania in bipolar I disorderof treatment; in patients with marked or worse baseline
severity, the odds of shifting to the Mild/No Symptoms
category were even greater (OR [95% CI])=4.0 [2.1, 7.7]).
When concurrent shift in the 4 core YMRS items was
analysed in the Moderate/Worse Symptoms category, 51% of
cariprazine patients compared with 29% of placebo patients
improved to Mild/No Symptoms at end of treatment
(p=0.0002). These results suggest that clinically relevant
improvement occurred in a signiﬁcantly greater proportion
of cariprazine- than placebo-treated patients on these key
items. Although an analysis was planned to evaluate con-
current improvement on the core items in patients in the
Marked/Worse Symptom category, it was not conducted
because the percentage of patients with a marked or worse
score on the disruptive–aggressive behaviour item was too low
to evaluate. Potential reasons for the low percentage of
patients with marked or worse baseline impairment in
disruptive–aggressive behaviour have been discussed
previously.
The percentage of patients who shifted from the Moder-
ate/Worse Symptom category at baseline to the Mild/No
Symptoms category on the 4 core YMRS items (pla-
cebo=29%; cariprazine=51%) may be analogous to the
predeﬁned criteria for remission used in the constituent
studies (YMRS r12). The validity of the shift data in
relation to the concept of remission is supported by the
similarity with remission rates for placebo (30%) and
cariprazine (46%) from a previous post-hoc pooled analysis
of data from the same 3 constituent studies (Yatham et al.,
2015). To put these earlier data into a broader context,
when using the YMRS r8 remission criterion, which is
similar to one recommended by the International Society
for Bipolar Disorders (YMRS o8) (Tohen et al., 2009),
remission rates of 19% for placebo and 30% for cariprazine
were found (Yatham et al., 2015). The lower rates of
remission using this more stringent cut-off may reﬂect the
short duration of these trials since improvement of this
magnitude may take longer than 3 weeks to occur.
The concept of remission implies that symptoms of the
speciﬁed condition, in this case bipolar mania, are absent or
nearly absent, and there has not been a concomitant increase
in symptoms of another condition (e.g., depression). As such,
it is noteworthy that a signiﬁcantly greater percentage of
cariprazine-treated patients (23%) relative to placebo-treated
patients (14%) had mild or no symptoms on all 11 YMRS items
at endpoint in these post-hoc analyses. Given our highly
symptomatic population at baseline, these ﬁndings, coupled
with the percentage of patients shifting to a less severe level
of symptoms concurrently on all 4 core YMRS items, may
reﬂect a multifaceted standard of remission and be one of the
more interesting indications of clinically meaningful improve-
ment and a true asymptomatic state.
Limitations of these analyses included their pooled, post-
hoc nature and lack of active comparator, suggesting that
results should be interpreted accordingly. In addition, the
constituent studies were of short duration so the full effect
of cariprazine may not have been established and they were
not powered to detect treatment differences in individual
symptoms. Conventional p values without adjustment for
multiple comparisons were used in the post-hoc analyses
and although this is typical in post-hoc analyses, random
chance may have played a role in determining statisticallysigniﬁcant differences. Patients with bipolar II disorder,
rapid cycling, and signiﬁcant depressive symptoms were
excluded from participation in the constituent studies; as
such, the ability to generalise these ﬁndings to other
populations on the bipolar spectrum is limited.
Evaluating patient-level data and individual symptom
improvement may help inform clinical decision making and
tailor treatment strategies in acute bipolar mania. In these
post-hoc analyses, treatment with cariprazine relative to
placebo improved individual symptoms associated with
acute mania and resulted in a statistically greater percen-
tage of patients with mild or no symptoms at the end of
treatment. Additionally, novel category shift analyses
showed that more cariprazine- than placebo-treated
patients shifted from a more severe category of baseline
symptoms to a Mild/No Symptoms category at end of
treatment. Collectively, results from these analyses suggest
that cariprazine had broad efﬁcacy across the individual
symptoms of acute mania and treatment may result in
clinically relevant improvement for adult patients with
bipolar I disorder.
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